Stratus Therapeutics
Qiao Lin is a skilled scientist with extensive experience in hematopoietic stem cell biology and pharmacology. Currently serving as Scientist II in In Vivo Hematopoietic Stem Cell Biology at Garuda Therapeutics, Qiao Lin is responsible for performing stem cell transplants in mice. Prior experience includes roles as Scientist II and Scientist I at Ampersand Biomedicines, focusing on the design and execution of studies for multi-specific antibodies. Qiao Lin's academic background includes a PhD in Environmental and Occupational Health and a Master of Public Health from the University of Pittsburgh, complemented by a Bachelor of Medicine from Shenyang Medical College. Previous research involves antimicrobial testing and drug delivery methods.
Stratus Therapeutics
4 followers
Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution.